Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK has monetised its licence with CureVac through a settlement linked to CureVac’s 7 Aug 2025 agreement with BioNTech. The company will receive an immediate $370 million payment ($320 m cash) and collect a 1 % royalty on all 2025-onward US sales of Pfizer/BioNTech influenza, COVID-19 and combination mRNA vaccines.
The settlement also amends the CureVac licence, materially reducing future royalties that GSK would owe on its own mRNA pipeline products.
- Contingent upside: if BioNTech’s proposed acquisition of CureVac closes, GSK gains an extra $130 m cash, a further 1 % royalty on ex-US sales of the same vaccines and lower milestone obligations.
- Accounting: the $370 m is booked as other operating income (adjusting item) in Q3-2025; future royalties flow through total & core results.
- Litigation: GSK’s separate patent suits against Pfizer/BioNTech continue in the US and Europe.
- Strategic: GSK will tender its ≈16.6 m CureVac shares under the forthcoming offer.
The deal delivers near-term cash, creates recurring high-margin royalty streams and lowers eventual COGS for GSK’s own mRNA vaccines, though additional proceeds depend on the CureVac acquisition closing and legal uncertainties persist.
GSK plc filed a Form 6-K disclosing the latest tranche of its ongoing share buy-back programme. On 7 August 2025 the company repurchased 502,466 ordinary shares (31¼ p nominal) through Merrill Lynch International at prices between 1,361.00 p and 1,385.50 p, delivering a volume-weighted average price of 1,376.94 p.
These shares will be held in treasury, lifting treasury holdings to 239,545,027 shares, equal to 5.88 % of total voting rights. Shares in issue ex-treasury now stand at 4,075,843,458. Since the non-discretionary agreement with the broker began on 4 June 2025, GSK has acquired 21,410,644 shares under the programme.
The disclosure provides investors with the denominator for holdings notifications under UK Listing Rule DTR 5 and confirms that the buy-back remains within the previously announced authorisation.
GSK plc reports that, under its existing share buyback programme, it repurchased 498,759 ordinary shares (31¼p nominal) on 05 Aug 2025 through Merrill Lynch International at prices between 1,388.00p–1,412.50p, producing a VWAP of 1,397.84p. The shares will be held in treasury.
Since the non-discretionary mandate began on 4 Jun 2025, GSK has bought back 20,404,162 shares. Following the latest purchase the company now holds 238,538,545 treasury shares and has 4,076,849,940 ordinary shares in issue excluding treasury. Treasury shares account for 5.85 % of total voting rights, leaving 4,076,849,940 voting rights outstanding.
The filing provides trading-venue detail for compliance with FCA Disclosure Guidance & Transparency Rules and updates investors’ denominator for any shareholding notification requirements.
GSK plc has filed a Form 6-K to meet Financial Conduct Authority (FCA) Disclosure Guidance & Transparency Rule 5.6.1R. As of 31 July 2025 the company had 4,315,385,410 issued Ordinary Shares of 31 ¼ pence each. Of these, 237,044,421 shares were held in treasury, leaving 4,078,340,989 voting rights in circulation. Shareholders should use this denominator when calculating threshold notifications of holdings under FCA rules. The notice was authorised by Company Secretary V. A. Whyte and filed on 1 August 2025.
GSK plc filed a Form 6-K detailing a routine share repurchase executed on 31 July 2025 under its June-2025 non-discretionary buy-back mandate.
- Shares bought: 474,100 ordinary shares (nominal 31¼ p).
- Price range: 1,404.50–1,461.00 GBp; VWAP 1,423.11 GBp.
- Cumulative purchases since 4 June 2025: 18,910,038 shares.
The shares will be held in treasury, increasing the treasury balance to 237,044,421. Shares in issue (excluding treasury) now total 4,078,340,989, establishing the new denominator for voting-rights disclosures. Treasury stock represents 5.81 % of total voting rights.
No operational, earnings or guidance updates were provided; the filing primarily fulfils UK DTR 5.5.1R disclosure requirements.
Q2-25 snapshot: GSK generated turnover of £7.99 bn (+1% AER, +6% CER), led by Specialty Medicines (£3.33 bn, +15% CER) and Vaccines (£2.09 bn, +9% CER). Core operating profit rose 12% to £2.63 bn, lifting core margin 1.8 ppts to 32.9%; core EPS advanced 15% to 46.5 p. Total EPS climbed 35% on lower contingent-consideration charges. Cash generated from operations grew 47% to £2.43 bn, translating into £1.13 bn of free cash flow.
Guidance & capital returns: Management now expects FY-25 turnover, core operating profit and core EPS to reach the top end of prior 3-5%, 6-8% and 6-8% CER ranges. A 16 p dividend was declared (64 p FY target) and £822 m of a £2 bn buy-back executed in H1.
Pipeline momentum: Three FDA approvals received YTD (Penmenvy, Blujepa, Nucala-COPD); five major approvals targeted in 2025, with 14 late-stage assets each aiming for >£2 bn PYS. Phase III tebipenem stopped early for efficacy.
Key watch-points: General Medicines declined 6% CER, U.S. Shingrix demand softened and pricing pressure from U.S. IRA persisted. Core R&D spend increased 11% and included a £471 m impairment (belrestotug). Net debt edged to £13.7 bn after £0.8 bn acquisitions, £1.3 bn dividends and £0.8 bn buy-backs.